Robert Hershberg - 18 Jun 2025 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Reporting relationship: Director
Issuer ticker: RXRX
Reported as of: 18 Jun 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 23 Jun 2025, 17:23:23 UTC
Prior SEC filing: 12 Mar 2025
Next SEC filing: 17 Sep 2025
Source filing: View source filing
Reporting owner signature: /s/ Jonathan Golightly, attorney-in-fact

Key filing fact

Robert Hershberg filed Form 4 for RECURSION PHARMACEUTICALS, INC. (RXRX) on 23 Jun 2025.

Key facts

This page summarizes Robert Hershberg's Form 4 filing for RECURSION PHARMACEUTICALS, INC. (RXRX).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 23 Jun 2025, 17:23.

Change

Previous filing in this sequence was filed on 12 Mar 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001274139 Primary reporting owner

HERSHBERG ROBERT

Relationship: Director
Address: C/O RECURSION PHARMACEUTICALS, 41 S. RIO GRANDE STREET, SALT LAKE CITY
Signature: /s/ Jonathan Golightly, attorney-in-fact
Signature date: 23 Jun 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RXRX transaction

Class A Common Stock

Award

Transaction value: $0
Shares: +22,016
Change %: +43%
Price: $0.000000
Shares after: 73,732
Date: 18 Jun 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RXRX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +44,031
Change %
Price: $0.000000
Shares after: 44,031
Date: 18 Jun 2025
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 44,031
Exercise price: $5.11
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy. The restricted stock units will vest on the earlier of June 18, 2026 or the day prior to the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer.

Footnote F2

The shares subject to this option will vest and become exercisable on the earlier of June 18, 2026 or the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer.